Aurobindo Pharma is currently trading at Rs 186.80, up by 1.10 points or 0.59% from its previous closing of Rs 185.70 on the BSE.
The scrip opened at Rs 186.00 and has touched a high and low of Rs 187.60 and Rs 184.30 respectively. So far 88710 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 204.90 on 07-Jan-2013 and a 52 week low of Rs 99.65 on 10-Aug-2012.
Last one week high and low of the scrip stood at Rs 188.50 and Rs 169.10 respectively. The current market cap of the company is Rs 5435.46 crore.
The promoters holding in the company stood at 54.84% while Institutions and Non-Institutions held 31.87 % and 13.29% respectively.
Aurobindo Pharma has reported that Aurobindo Pharma USA, the company’s subsidiary has voluntarily recalled two lots of the anti-hypertensive Lisinopril tablets, 30 mg, from the US market due to a labeling error.
The company initiated the recall on April 9 as the label on the bottles of the drug mentioned the incorrect strength. The recall has been classified under Class-III, which the USFDA defines as products that are unlikely to cause any adverse health reaction but violate FDA labeling or manufacturing laws.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: